Immune checkpoint inhibitors (ICI) including programmed death-1 (PD-1) inhibitors, programmed death ligand-1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors promote immune-mediated targeted killing of tumour cells. The gene discussed is CTLA4; the disease is neoplasm.